Article: DOR BioPharma Reports Fourth Quarter and Year End Financial Results and Accomplishments for 2003.

Business Editors/Health/Medical Writers

MIAMI--(BUSINESS WIRE)--March 31, 2004

DOR BioPharma, Inc., (AMEX:DOR), a biopharmaceutical company focused on biodefense vaccines and therapeutics for unmet medical needs, today announced financial results for the fourth quarter and year ended December 31, 2003.

Net loss for fourth quarter 2003 was approximately $1.4 million, or $0.05 per share, compared to $1.1 million, or $0.05 per share, for fourth quarter 2002. The Company's net loss for the year 2003 was approximately $6.2 million, or $0.21 per share, compared to $6.4 million, or $0.29 per share, for the year 2002. The increased net loss for the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!